Don't want to miss the best from Business Standard?
Glenmark Pharma today reported 3.46 per cent rise in consolidated net profit to Rs 223.58 crore for the second quarter ended September 30, 2016-17.
It had reported net profit of Rs 216.10 crore for the July-September quarter of the 2015-16 fiscal, Glenmark said in a BSE filing.
Its consolidated revenue was up 16.48 per cent to Rs 2,224.10 crore during the quarter under review as against Rs 1,909.36 of the year-ago period.
Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said: "The overall business has gained good traction especially across key geographies. The entire emerging markets business ex-India which got severely hit in the past few years on account of currencies is also recuperating well."
For 6 months ended September 30, Glenmark's consolidated revenue was at Rs 4,193.49 crore, up 17.64 per cent from Rs 3,564.61 crore in the year-ago period.
"The US, India, ROW and the API business have done well in the first half of the financial year. The strong growth witnessed by the US business is on account of a number of product approvals received by the organization over the last 18 months," Saldanha said.
Glenmark stock settled at Rs 906.40, down 0.42 per cent, on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
